Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma is a paper indexed in PICO Portal from OpenAlex.
How many citations does Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma have?
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma has 401 citations in the OpenAlex counts PICO Portal stores.
When was Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma published?
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma has 2019 year in the PICO Portal index.
What is the open-access status of Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma?
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma has bronze oa status in the PICO Portal index.
What is the DOI of Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma?
The DOI for Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma is on the source record.
What is the PMID of Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma?
The PMID for Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma is on the source record.
What is the OpenAlex record for Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma?
The OpenAlex for Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma is on the source record.